组织转谷氨酰胺酶2在乙型肝炎病毒相关肝细胞癌中发挥促癌作用。
Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma.
作者信息
Yu Chengbo, Cao Qing, Chen Ping, Yang Shigui, Gong Xianli, Deng Min, Ruan Bing, Li Lanjuan
机构信息
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University School of Medicine, 79 Qingchun Rd, Hangzhou, 310003, China.
Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
出版信息
Tumour Biol. 2016 Dec;37:16269–16274. doi: 10.1007/s13277-016-5425-z. Epub 2016 Oct 25.
Hepatitis B virus (HBV) infection is a major risk factor which can lead to development of hepatocellular carcinoma (HCC). Tissue transglutaminase-2 (TG2) has been shown to be critical for cancer progression. However, how TG2 promotes the progression of HBV-related HCC remains unknown. In this study, we aimed to explore the expression and function of TG2 on HBV-related HCC progression. The expression levels of TG2 were examined in a series of HBV-related HCC tissues and a panel of HCC cell lines. The effects of TG2 knockdown on the proliferation and migration of HBV-related cells were determined. TG2 expression was found to be significantly upregulated in HBV-related HCC tissues. TG2 expression was higher in HBV-related HCC cell lines than HBV-unrelated HCC cell lines. Moreover, inhibition of TG2 in HCC cell lines HepG2.2.15 and Hep3B could inhibit cell proliferation, migration, and invasion in vitro. Our results indicated that TG2 could serve as a promising target for treatment of HBV-related HCC patients.
乙型肝炎病毒（HBV）感染是导致肝细胞癌（HCC）发生的主要危险因素。组织转谷氨酰胺酶2（TG2）已被证明对癌症进展至关重要。然而，TG2如何促进HBV相关HCC的进展仍不清楚。在本研究中，我们旨在探讨TG2在HBV相关HCC进展中的表达及功能。检测了一系列HBV相关HCC组织和一组HCC细胞系中TG2的表达水平。确定了敲低TG2对HBV相关细胞增殖和迁移的影响。发现TG2在HBV相关HCC组织中显著上调。与非HBV相关HCC细胞系相比，TG2在HBV相关HCC细胞系中的表达更高。此外，在HCC细胞系HepG2.2.15和Hep3B中抑制TG2可在体外抑制细胞增殖、迁移和侵袭。我们的结果表明，TG2可作为治疗HBV相关HCC患者的一个有前景的靶点。
Zotero 插件